Genentech and ImClone reported success in developing a pair of drugs that treat head and neck cancer and lung cancer, respectively. Genentech said combining its Tarceva and Avastin can extend the survival rate of patients with lung cancer and ImClone said Erbitux, FDA-approved for treating colon cancer, can work with radiation to increase the median survival rate of patients with head and neck cancer.

Related Summaries